Is REPL Stock Undervalued?

A comprehensive valuation analysis of Replimune Group Inc (REPL) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated June 25, 2026•8 min read•View Full Analysis

Valuation Verdict

→

Fairly Valued

0.0% downside risk

Based on our analysis, Replimune Group Inc appears to be fairly valued at the current price of $0.00.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing REPL relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

N/A

P/B Ratio

3.44

High

P/S Ratio

N/A

EV/EBITDA

N/A

Understanding the Metrics

P/E Ratio: Not currently profitable or data unavailable.
P/B Ratio: A P/B of 3.44 means investors pay $3.44 for every $1 of book value.
P/S Ratio: Revenue data not available.
EV/EBITDA: EBITDA data not available.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Replimune Group Inc stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$0.00

Fair Value Estimate

N/A

Unable to calculate a reliable fair value estimate due to insufficient financial data or negative cash flows. This is common for early-stage growth companies or those undergoing restructuring.

Investment Conclusion

Bottom Line

Replimune Group Inc (REPL) appears fairly valued at $0.00, trading in line with our fundamental analysis. The stock may be appropriate for investors seeking exposure to Healthcare without significant valuation risk.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.